Revenue: As of FY2025 Q3, the actual value is USD 753 K.

EPS: As of FY2025 Q3, the actual value is USD -0.11.

EBIT: As of FY2025 Q3, the actual value is USD -24.39 M.

Segment Revenue

• Total revenue for the third quarter of 2025 was $0.8 million, with $0.7 million from U.S. sales of Symvess and $0.1 million from a research collaboration.
• Revenue for the first nine months of 2025 was $1.6 million, with $0.9 million from U.S. sales of Symvess and $0.6 million from the research collaboration.

Operational Metrics

• Cost of goods sold was $0.3 million for the third quarter and $0.6 million for the first nine months of 2025.
• Research and development expenses decreased to $17.3 million for the third quarter of 2025 from $22.9 million in the same period of 2024, and to $54.7 million for the first nine months of 2025 from $67.9 million in the same period of 2024.
• Selling, general and administrative expenses were $7.6 million for the third quarter of 2025, up from $7.3 million in the same period of 2024, and $23.6 million for the first nine months of 2025, up from $18.4 million in the same period of 2024.
• Net loss was $17.5 million for the third quarter of 2025, compared to $39.2 million for the same period in 2024, and $16.0 million for the first nine months of 2025, compared to $127.8 million for the same period in 2024.

Cash Flow

• The company reported cash, cash equivalents, and restricted cash of $19.8 million as of September 30, 2025.
• Total net cash used in operating activities was $78.9 million for the first nine months of 2025, compared to $71.5 million for the same period in 2024.

Unique Metrics

• The company completed the sale of common stock and warrants resulting in net proceeds of approximately $56.5 million subsequent to September 30, 2025.

Outlook / Guidance

• Humacyte plans to advance the Coronary Tissue Engineered Vessel (CTEV) into a first-in-human study in CABG in 2026, with an IND application submitted to the FDA.
• The company aims to submit a supplemental BLA for the ATEV in dialysis in the second half of 2026, subject to interim results from ongoing trials.
• Humacyte is expanding its intellectual property estate with a new U.S. patent for its bioengineered esophagus, complementing existing patents for urinary conduits and tracheas.